Fractyl nets $55M for intestine-resurfacing trial in Type 2 diabetes

Fractyl Laboratories
Fractyl’s CE-marked Revita device uses water and heat to strip away the mucosal layers inside the duodenum, which can thicken after years of exposure to dietary fats, sugars and other foods and upset metabolic hormone balances. (Photo: Fractyl Laboratories)

Fractyl Laboratories, developers of a minimally invasive procedure to resurface the inner linings of the intestine, has raised $55 million to help complete its pivotal clinical trial in Type 2 diabetes.

The study aims to examine the treatment’s effects on blood sugar control and a person’s need for insulin injections. The former Fierce 15 winner’s Revita device has also shown improvements in liver fat, linked to diseases such as nonalcoholic steatohepatitis, or NASH.

“Type 2 diabetes and NAFLD/NASH are eroding our global health and are responsible for a large portion of global healthcare costs,” said Michael Huang, a managing partner at Taiwania, who joined Fractyl’s board of directors after the firm led its series E round.

Event

Join the world's top medtech executives virtually for the leading event in medtech — The Virtual MedTech Conference by AdvaMed

Expect the same high-quality education, world-class speakers and valuable business development in a virtual format. Experience more of the conference with on demand content and partnering, as well as livestreamed sessions.

Other participants included the company’s returning investors Bessemer Venture Partners, General Catalyst, Domain Associates, Mithril Capital Management, Emergent Medical Partners, True Ventures and GV, as well as new backers in Catalio Capital Management, CDIB Venture Capital Corp., and YJ Capital. 

RELATED: Fractyl's intestine-resurfacing device shows gains in HbA1c and liver fat, plus 2-year data

Fractyl’s CE-marked Revita device uses water and heat to strip away the mucosal layers inside the duodenum, allowing it to regrow naturally. The company says that lining can thicken after years of exposure to dietary fats, sugars and other foods, upsetting the balance of hormones linked to metabolic pathways, related diseases and resistance to insulin.

The primary endpoint of the U.S. clinical trial set to launch later this year will explore the percentage of participants who can achieve target glycemic control without needing insulin for 24 weeks, compared to a sham treatment.

“Fractyl's founding mission was to find a better way to treat type 2 diabetes by addressing the root cause of disease that can reverse the disease process rather than manage its symptoms,” co-founder and CEO Harith Rajagopalan said. “We now have data from hundreds of patients with type 2 diabetes showing the durable benefits of a single Revita treatment.”

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.